| Objective: Pancreatic cancer is one of the most malignant tumors with poor prognosis in the digestive system and has a propensity to relapse in many patients even after radical surgery.Intraperitoneal hyperthermic perfusion(IPHP)has the characteristics of high-temperature killing and mechanical flushing of tumor cells.IPHP has been applied to the treatment of advanced pancreatic cancer patients and achieved excellent results but infrequently reported in treating resectable pancreatic cancer.This study aimed to evaluate the safety and efficacy of pancreaticoduodenectomy plus intraperitoneal hyperthermic perfusion(PD + IPHP)in patients with pancreatic head cancer.Methods:From July 2017 to December 2019,data of pancreatic cancer patients undergoing pancreaticoduodenectomy were retrospectively analyzed,including PD + IPHP(n = 28)and PD group(n=29).IPHP was performed during surgery,on postoperative day(POD)2,and POD 4 with normal saline as the perfusion solution.Complications and overall survival of these patients were observed and recorded.Results:There was no significant difference in the incidence of major postoperative complications between PD + IPHP and PD groups.The median overall survival(OS)time of the PD + IPHP group was 19.0 months,the 1-year survival rate was 82.35%,and the 2-year survival rate was 49.41%.The median OS time of the PD group was 13.0 months,the 1-year survival rate was 51.00%,and the 2-year survival rate was 27.33%(Log-rank,P = 0.030;Breslow,P = 0.039).Cox proportional risk model showed that IPHP was an independent factor to improve survival outcomes of these patients(P = 0.038;HR = 0.363,95% CI: 0.14-0.94).Conclusion:IPHP can significantly prolong the OS of patients with pancreatic head cancer receiving radical surgery and does not increase the incidence of anastomotic leakage and other complications. |
PDF Full Text Request